Interpace Biosciences Stock Revenue
Interpace Biosciences fundamentals help investors to digest information that contributes to Interpace Biosciences' financial success or failures. It also enables traders to predict the movement of Interpace OTC Stock. The fundamental analysis module provides a way to measure Interpace Biosciences' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Interpace Biosciences otc stock.
Interpace |
Interpace Biosciences OTC Stock Revenue Analysis
Interpace Biosciences' Revenue is income that a firm generates from business activities such us rendering services or selling goods to customers. It is a crucial part of a business and an essential item when evaluating a company's financial statements. Revenues from a firm's primary business operations can be reported on the income statement as sales revenue, net sales, or simply sales, depending on the industry in which a given company operates.
Current Interpace Biosciences Revenue | 41.31 M |
Most of Interpace Biosciences' fundamental indicators, such as Revenue, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Interpace Biosciences is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Revenue is typically recorded when cash or cash equivalents are exchanged for services or goods and can include products or services discounts, promotions, as well as early payments on invoices or services rendered in advance.
CompetitionBased on the latest financial disclosure, Interpace Biosciences reported 41.31 M of revenue. This is 99.46% lower than that of the Health Care Providers & Services sector and 97.92% lower than that of the Health Care industry. The revenue for all United States stocks is 99.56% higher than that of the company.
Interpace Revenue Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Interpace Biosciences' direct or indirect competition against its Revenue to detect undervalued stocks with similar characteristics or determine the otc stocks which would be a good addition to a portfolio. Peer analysis of Interpace Biosciences could also be used in its relative valuation, which is a method of valuing Interpace Biosciences by comparing valuation metrics of similar companies.Interpace Biosciences is currently under evaluation in revenue category among its peers.
Interpace Fundamentals
| Return On Equity | -2.85 | ||||
| Return On Asset | -0.26 | ||||
| Profit Margin | (0.59) % | ||||
| Operating Margin | (0.28) % | ||||
| Current Valuation | 11.72 M | ||||
| Shares Outstanding | 4.27 M | ||||
| Shares Owned By Insiders | 28.12 % | ||||
| Number Of Shares Shorted | 47.35 K | ||||
| Price To Earning | (1.07) X | ||||
| Price To Book | 10.04 X | ||||
| Price To Sales | 0.10 X | ||||
| Revenue | 41.31 M | ||||
| Gross Profit | 17.95 M | ||||
| EBITDA | (9.12 M) | ||||
| Net Income | (14.94 M) | ||||
| Cash And Equivalents | 1.86 M | ||||
| Cash Per Share | 0.44 X | ||||
| Total Debt | 9.44 M | ||||
| Debt To Equity | 6.55 % | ||||
| Current Ratio | 0.61 X | ||||
| Book Value Per Share | (14.51) X | ||||
| Cash Flow From Operations | (8.72 M) | ||||
| Short Ratio | 0.19 X | ||||
| Earnings Per Share | (3.12) X | ||||
| Target Price | 11.0 | ||||
| Number Of Employees | 147 | ||||
| Beta | 0.82 | ||||
| Market Capitalization | 5.16 M | ||||
| Total Asset | 38.43 M | ||||
| Retained Earnings | (172.59 M) | ||||
| Working Capital | (4.21 M) | ||||
| Current Asset | 19.16 M | ||||
| Current Liabilities | 23.37 M | ||||
| Z Score | -4.6 | ||||
| Net Asset | 38.43 M |
Currently Active Assets on Macroaxis
Check out Risk vs Return Analysis to better understand how to build diversified portfolios. Also, note that the market value of any otc stock could be closely tied with the direction of predictive economic indicators such as signals in interest. You can also try the Latest Portfolios module to quick portfolio dashboard that showcases your latest portfolios.
Other Consideration for investing in Interpace OTC Stock
If you are still planning to invest in Interpace Biosciences check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Interpace Biosciences' history and understand the potential risks before investing.
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
| Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
| Content Syndication Quickly integrate customizable finance content to your own investment portal | |
| Equity Valuation Check real value of public entities based on technical and fundamental data | |
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
| Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
| Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes | |
| Bonds Directory Find actively traded corporate debentures issued by US companies | |
| Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators |